Milestone Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:MIST) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Total assets 75.5 M61.88 M47.42 M87.75 M113.56 M Total liabilities 62.35 M68.01 M65.16 M67.25 M71.79 M Total equity 13.15 M-6.12 M-17.75 M20.5 M41.77 M Total liabilities & shareholders' equities 75.5 M61.88 M47.42 M87.75 M113.56 M Total debt 54.8 M55.05 M55.88 M56.73 M58.38 M Net debt -14.9 M-955 K12.48 M-25.88 M-47.62 M

Haberler

Milestone Pharmaceuticals gerçek dünya PSVT kayıt çalışması planlıyor

Raymond James, Milestone Pharmaceuticals hissesine Güçlü Al önerisiyle başladı

Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

Milestone Pharmaceuticals hisse senedi düştü, tahminleri karşıladı

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Stock: Downgrading To Sell As CARDAMYST Faces A Tough Reality (NASDAQ:MIST)

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Milestone’un PSVT tedavisi CARDAMYST artık ABD eczanelerinde satışta

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)

Avrupa düzenleyicileri PSVT için etripamil burun spreyi başvurusunu kabul etti